View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 25, 2019

Opiant Pharmaceuticals bulimia nervosa drug fails trial

Opiant Pharmaceuticals has reported negative top-line results from the Phase II clinical trial conducted to study its naloxone product OPNT001 to treat bulimia nervosa, a potentially life-threatening eating disorder.

Opiant Pharmaceuticals has reported negative top-line results from the Phase II clinical trial conducted to study its naloxone product OPNT001 to treat bulimia nervosa, a potentially life-threatening eating disorder.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Formulated as a nasal spray, OPNT001 is an opioid antagonist candidate. It is said to have demonstrated a rapid absorption profile.

The Phase II trial failed to meet the primary endpoint of minimising the number of binging days from baseline to week eight. Key secondary efficacy endpoints of the study were also not met.

However, the therapeutic was observed to be generally safe and well-tolerated, with adverse events being minimal.

“The company’s focus for 2019 remains on conducting the pivotal trial for OPNT003, nasal nalmefene for opioid overdose.”

Opiant Pharmaceuticals conducted the randomised, double-blind, placebo-controlled trial in up to 80 UK patients to assess OPNT001’s safety, tolerability and effect on clinical outcomes such as changes in eating behaviour.

Based on the data obtained during the trial, the company decided to cease the development of the product for bulimia nervosa and focus on other candidates in its pipeline.

Opiant Pharmaceuticals CEO Roger Crystal said: “The company’s focus for 2019 remains on conducting the pivotal trial for OPNT003, nasal nalmefene for opioid overdose, preparing to enrol patients into a Phase II study for OPNT002, nasal naltrexone, for the treatment of Alcohol Use Disorder and progressing the development of OPNT004, drinabant, for acute cannabinoid overdose.”

Bulimia Nervosa patients suffer from binge eating that is followed by strategies such as purging and fasting to prevent weight gain. The disorder could also lead to psychiatric disorders, including depression, anxiety and substance abuse.

Fluoxetine is currently the only medication approved by the US Food and Drug Administration (FDA) to treat bulimia nervosa.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena